Breaking News: Japan First in the World to Approve Dupilumab for CSU
The Dermatology Digest
FEBRUARY 16, 2024
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.
Let's personalize your content